SBIR-STTR Award

Ribonucleosides for Prediction of Skin Irritation
Award last edited on: 7/2/08

Sponsored Program
SBIR
Awarding Agency
NIH : NIEHS
Total Award Amount
$100,000
Award Phase
1
Solicitation Topic Code
114
Principal Investigator
William G Reifenrath

Company Information

Stratacor Inc

1315 South 46th Street Building 154
Richmond, CA 94804
   (510) 231-9463
   info@Stratacor-Inc.com
   www.Stratacor-Inc.com
Location: Single
Congr. District: 11
County: Contra Costa

Phase I

Contract Number: 1R43ES010091-01
Start Date: 9/30/99    Completed: 3/31/00
Phase I year
1999
Phase I Amount
$100,000
Biochemical measurements of skin integrity were conducted to measure the skin s response to toxic chemicals, which included aqueous solutions of sodium fluoride or lead acetate, and xylene solution of benzo [a] pyrene as positive controls. Receptor fluid bathing the visceral side of excised pig skin was assays for lactate production as an indicator of the main energy- producing pathways, for the enzyme lactic acid dehydrogenase (LDH) as an indicator of cell lysis, for color changes in a redox dye to indicate alteration in the oxidation-reduction capacity of the tissue, for RNA nucleosides as an indicator of aberrant RNA metabolism, and for accumulation of mutagenic products. Alteration of pyrimidine nucleoside excretion by skin was the most sensitive indicator of exposure to chemical or biological insults. We propose that alterations in ribonucleosides from excised skin will serve as sensitive indicators of exposure to skin irritants. We further propose to conduct such tests using a novel diffusion cell array based on standard 24 well culture plates. PROPOSED COMMERCIAL APPLICATION Development of new materials that contact the skin (e.g. topical drugs, cosmetics) usually requires an assessment of skin irritation potential in an animal model. There is a demand in commerce for an in vitro test that would reduce animal usage and produce results more predictive for man. Development of our technology will provide such a test with significant advantages over currently available test kits.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----